The Texas Interprofessional Pharmacogenomics (IPGx) PILOT Cohort
Texas A&M University
Summary
The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity/saturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice.
Description
The investigators are concerned with patient safety and ADRs as these areas of clinical practice represent significant causes of death, ahead of many of the better recognized acute and chronic causes of mortality. While prescribing medicines can have life-altering benefits, a more precise way of choosing among the options on a formulary continues to lag behind existing technologies. A person's drug response can vary by means of drug-drug or drug-food interactions, as well as by sex, age, and disease status. Large interpersonal variabilities of up to 1000-fold exist in response to the same dose…
Eligibility
- Age range
- 45+ years
- Sex
- All
- Healthy volunteers
- Not specified
Inclusion Criteria: * People taking 5 or more medications, including over the counter drugs, supplements, natural products, cannabis produces, or other recreational drugs * Ability to give and comprehend the consent process. * Consent to donate urine samples, genetic data through buccal swabs, undergo a comprehensive history and physical examination. * All genders. * Age 45 and over Exclusion Criteria: * Subject has been diagnosed or is being treated for any cancer other than basal cell cancer in the last 5 years. Patients with metastatic melanoma in the last 5 years will be excluded. * Adm…
Location
- The Interprofessional Pharmacogenomics (IPGx) ClinicBryan, Texas